RxDoctor Payments Data

Mayank Yadav

Cardiology · Orange City, FLNPI 1134535396

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.0%), travel and lodging and grants — rather than concentrated in one kind of arrangement. Medtronic accounts for 64.1% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $2,897, more than ten times the $19 reported in 2021.

$6,954in general payments, 2019–2025

Across 113 payments — averaging $61.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$603
  • Boston Scientific$368
  • Terumo Medical Corporation$270
  • Abiomed$269
  • Novartis$203
  • plus $783 from 10 others

What the payments were for

  • Grants$1001%
  • Travel & lodging$3,30548%
  • Food & beverage$3,54951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,954 in reported general payments places this provider in the 85th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$287,266
Medicare patients
454
Services billed
1,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$59,227
EntrestoSacubitril/Valsartan62$46,516
XareltoRivaroxaban20$22,939
JardianceEmpagliflozin17$16,334
BrilintaTicagrelor14$10,374
Olmesartan Medoxomil112$1,675
Atorvastatin Calcium154$1,629
Metoprolol Succinate165$1,610
Ranolazine ErRanolazine14$1,511
Furosemide257$1,082
Rosuvastatin Calcium64$776
Losartan Potassium96$750
Spironolactone97$687
Carvedilol69$663
Amlodipine Besylate112$576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$203$46,51662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 cardiology providers in Florida.

Other cardiology in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →